Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Intraductal, Noninfiltrating | 6 | 2020 | 949 | 1.360 |
Why?
|
Melanoma | 24 | 2022 | 5510 | 1.100 |
Why?
|
Mammography | 16 | 2024 | 2476 | 1.050 |
Why?
|
Breast Neoplasms | 22 | 2024 | 20822 | 0.820 |
Why?
|
Skin Neoplasms | 19 | 2022 | 5686 | 0.780 |
Why?
|
SEER Program | 6 | 2020 | 1508 | 0.720 |
Why?
|
Early Detection of Cancer | 15 | 2024 | 3086 | 0.600 |
Why?
|
Models, Statistical | 13 | 2021 | 5102 | 0.590 |
Why?
|
Interferon-alpha | 8 | 2022 | 895 | 0.520 |
Why?
|
Simian immunodeficiency virus | 9 | 2014 | 846 | 0.470 |
Why?
|
Mass Screening | 10 | 2016 | 5255 | 0.460 |
Why?
|
Risk Assessment | 12 | 2021 | 23338 | 0.450 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.430 |
Why?
|
Health Status Disparities | 1 | 2023 | 1797 | 0.410 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 6 | 2013 | 570 | 0.390 |
Why?
|
Viremia | 7 | 2014 | 736 | 0.290 |
Why?
|
Computer Simulation | 8 | 2021 | 6196 | 0.290 |
Why?
|
Schistosomiasis mansoni | 3 | 2011 | 85 | 0.240 |
Why?
|
Carboplatin | 5 | 2015 | 801 | 0.240 |
Why?
|
Breast Self-Examination | 1 | 2003 | 34 | 0.230 |
Why?
|
Macaca mulatta | 9 | 2014 | 2375 | 0.230 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 11524 | 0.220 |
Why?
|
Survival Analysis | 9 | 2019 | 10252 | 0.210 |
Why?
|
Neoplasm Staging | 14 | 2022 | 11031 | 0.210 |
Why?
|
Niacinamide | 5 | 2015 | 417 | 0.200 |
Why?
|
Survival Rate | 8 | 2021 | 12788 | 0.190 |
Why?
|
Prognosis | 15 | 2021 | 29063 | 0.190 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2022 | 104 | 0.190 |
Why?
|
Phenylurea Compounds | 5 | 2015 | 528 | 0.190 |
Why?
|
United States | 19 | 2024 | 69872 | 0.190 |
Why?
|
Aged | 34 | 2024 | 163280 | 0.180 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2018 | 288 | 0.180 |
Why?
|
Disease Susceptibility | 4 | 2019 | 1782 | 0.180 |
Why?
|
Paclitaxel | 5 | 2015 | 1708 | 0.180 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 903 | 0.180 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2002 | 214 | 0.180 |
Why?
|
Middle Aged | 40 | 2024 | 213383 | 0.180 |
Why?
|
Early Diagnosis | 1 | 2004 | 1184 | 0.170 |
Why?
|
Models, Biological | 3 | 2018 | 9583 | 0.170 |
Why?
|
Melanoma, Amelanotic | 1 | 2019 | 18 | 0.170 |
Why?
|
Adjuvants, Immunologic | 2 | 2022 | 1000 | 0.170 |
Why?
|
Female | 52 | 2024 | 380194 | 0.170 |
Why?
|
Population Surveillance | 2 | 2014 | 2616 | 0.160 |
Why?
|
Disease Progression | 6 | 2022 | 13284 | 0.160 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1061 | 0.150 |
Why?
|
HIV Envelope Protein gp160 | 3 | 2014 | 99 | 0.150 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 3 | 2014 | 127 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2022 | 9239 | 0.150 |
Why?
|
Adult | 35 | 2024 | 214055 | 0.150 |
Why?
|
Nevus | 1 | 2019 | 204 | 0.150 |
Why?
|
Disease-Free Survival | 11 | 2019 | 6895 | 0.140 |
Why?
|
Aged, 80 and over | 16 | 2021 | 57776 | 0.140 |
Why?
|
Incidence | 7 | 2020 | 20947 | 0.140 |
Why?
|
Herpes Genitalis | 2 | 2009 | 141 | 0.140 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12354 | 0.140 |
Why?
|
Humans | 64 | 2024 | 744343 | 0.140 |
Why?
|
Chronic Disease | 4 | 2007 | 9146 | 0.140 |
Why?
|
Herpesvirus 2, Human | 2 | 2009 | 189 | 0.140 |
Why?
|
Immunity, Mucosal | 3 | 2014 | 490 | 0.140 |
Why?
|
Sputum | 1 | 2017 | 476 | 0.130 |
Why?
|
Schistosoma mansoni | 3 | 2011 | 149 | 0.130 |
Why?
|
HIV-1 | 7 | 2014 | 6939 | 0.130 |
Why?
|
Receptors, Estrogen | 3 | 2024 | 2187 | 0.120 |
Why?
|
Selenium | 2 | 2017 | 405 | 0.120 |
Why?
|
Gene Products, gag | 2 | 2014 | 337 | 0.120 |
Why?
|
Direct Service Costs | 1 | 2014 | 62 | 0.120 |
Why?
|
Cyclosporins | 2 | 2004 | 220 | 0.120 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4149 | 0.110 |
Why?
|
Vaccination | 4 | 2014 | 3278 | 0.110 |
Why?
|
Immunity | 1 | 2019 | 1012 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 7 | 2018 | 6538 | 0.110 |
Why?
|
Vaccines, Attenuated | 1 | 2013 | 342 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2019 | 9959 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2022 | 2043 | 0.100 |
Why?
|
Heterosexuality | 1 | 2013 | 276 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 3479 | 0.100 |
Why?
|
Young Adult | 13 | 2022 | 56430 | 0.100 |
Why?
|
Lymphocyte Subsets | 2 | 2010 | 315 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2022 | 9438 | 0.100 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2013 | 599 | 0.100 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 370 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 509 | 0.090 |
Why?
|
False Positive Reactions | 4 | 2016 | 981 | 0.090 |
Why?
|
Age Factors | 5 | 2019 | 18370 | 0.090 |
Why?
|
Antineoplastic Agents | 6 | 2019 | 13695 | 0.090 |
Why?
|
Listeria monocytogenes | 1 | 2011 | 250 | 0.090 |
Why?
|
Mucous Membrane | 2 | 2010 | 673 | 0.090 |
Why?
|
Integrins | 1 | 2013 | 846 | 0.080 |
Why?
|
Family Characteristics | 1 | 2013 | 1000 | 0.080 |
Why?
|
Public Health | 1 | 2002 | 2603 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2009 | 169 | 0.080 |
Why?
|
Recombinant Proteins | 5 | 2017 | 6622 | 0.080 |
Why?
|
RNA, Small Interfering | 2 | 2009 | 3505 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 1182 | 0.080 |
Why?
|
AIDS Vaccines | 1 | 2014 | 938 | 0.080 |
Why?
|
Mortality | 4 | 2024 | 2864 | 0.070 |
Why?
|
Adenoviridae | 1 | 2011 | 1099 | 0.070 |
Why?
|
HIV Infections | 7 | 2013 | 16718 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2012 | 956 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5221 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 1941 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2014 | 1023 | 0.070 |
Why?
|
Viral Load | 6 | 2011 | 3299 | 0.070 |
Why?
|
Male | 25 | 2022 | 350118 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 640 | 0.070 |
Why?
|
Viral Vaccines | 1 | 2011 | 636 | 0.070 |
Why?
|
Autoantibodies | 1 | 2014 | 2035 | 0.070 |
Why?
|
Adolescent | 10 | 2022 | 85781 | 0.070 |
Why?
|
Sensitivity and Specificity | 6 | 2014 | 14722 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39050 | 0.070 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.060 |
Why?
|
Massachusetts | 1 | 2018 | 8663 | 0.060 |
Why?
|
Time Factors | 8 | 2021 | 40075 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2734 | 0.060 |
Why?
|
Genes, MDR | 1 | 2004 | 37 | 0.060 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 1038 | 0.060 |
Why?
|
Biometry | 1 | 2007 | 558 | 0.060 |
Why?
|
HIV Core Protein p24 | 1 | 2004 | 256 | 0.060 |
Why?
|
Viral Envelope Proteins | 1 | 2007 | 635 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4851 | 0.060 |
Why?
|
Drug Resistance, Multiple | 1 | 2004 | 252 | 0.060 |
Why?
|
DNA Methylation | 1 | 2017 | 4286 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 547 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 272 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.060 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1344 | 0.050 |
Why?
|
Virus Replication | 5 | 2011 | 2534 | 0.050 |
Why?
|
Vincristine | 1 | 2004 | 1039 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10397 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2727 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2004 | 3589 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2009 | 3523 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2013 | 2958 | 0.050 |
Why?
|
Breast | 2 | 2024 | 1969 | 0.050 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2416 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13102 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
Oximes | 1 | 2022 | 311 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2013 | 4479 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2013 | 3297 | 0.050 |
Why?
|
Cytarabine | 3 | 2009 | 692 | 0.050 |
Why?
|
Vaccines, Synthetic | 2 | 2014 | 634 | 0.050 |
Why?
|
Health Planning | 1 | 2002 | 238 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2015 | 12026 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 170 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 648 | 0.040 |
Why?
|
Cohort Studies | 2 | 2020 | 40561 | 0.040 |
Why?
|
Treatment Outcome | 9 | 2021 | 63114 | 0.040 |
Why?
|
Vagina | 3 | 2010 | 825 | 0.040 |
Why?
|
Mitotic Index | 1 | 2019 | 172 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 1369 | 0.040 |
Why?
|
Hair Color | 1 | 2019 | 136 | 0.040 |
Why?
|
Epidemiologic Research Design | 1 | 2002 | 367 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2013 | 4386 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2017 | 53 | 0.040 |
Why?
|
Doxorubicin | 1 | 2004 | 2234 | 0.040 |
Why?
|
Pyridones | 1 | 2022 | 712 | 0.040 |
Why?
|
Probability | 1 | 2003 | 2505 | 0.040 |
Why?
|
Skin Ulcer | 1 | 2019 | 120 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1534 | 0.040 |
Why?
|
Daunorubicin | 2 | 2009 | 158 | 0.040 |
Why?
|
RGS Proteins | 1 | 2017 | 77 | 0.040 |
Why?
|
Administration, Intravaginal | 2 | 2009 | 150 | 0.040 |
Why?
|
Mutation | 3 | 2022 | 29786 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8428 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2018 | 3616 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4933 | 0.040 |
Why?
|
Dexamethasone | 1 | 2004 | 1951 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2825 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7880 | 0.040 |
Why?
|
Infant | 2 | 2016 | 35136 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2009 | 2987 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2007 | 3176 | 0.030 |
Why?
|
Child, Preschool | 2 | 2016 | 41006 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 25625 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2020 | 709 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2740 | 0.030 |
Why?
|
Osteopontin | 1 | 2017 | 296 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2011 | 1147 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2004 | 1873 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1836 | 0.030 |
Why?
|
Gene Products, nef | 1 | 2014 | 110 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5391 | 0.030 |
Why?
|
G(M2) Ganglioside | 1 | 2014 | 15 | 0.030 |
Why?
|
Child | 3 | 2022 | 77709 | 0.030 |
Why?
|
Liposomes | 2 | 2009 | 759 | 0.030 |
Why?
|
Gene Products, rev | 1 | 2013 | 31 | 0.030 |
Why?
|
Myelodysplastic Syndromes | 1 | 2004 | 1352 | 0.030 |
Why?
|
Risk Factors | 5 | 2021 | 72290 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2002 | 2258 | 0.030 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2013 | 159 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 162 | 0.030 |
Why?
|
Feces | 2 | 2011 | 1401 | 0.030 |
Why?
|
Antibodies, Neutralizing | 2 | 2014 | 1978 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2004 | 1596 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1915 | 0.030 |
Why?
|
Animals | 11 | 2014 | 168757 | 0.030 |
Why?
|
Genes, ras | 1 | 2015 | 690 | 0.030 |
Why?
|
Fusion Proteins, gag-pol | 1 | 2011 | 8 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2011 | 73 | 0.030 |
Why?
|
Remission Induction | 2 | 2009 | 2386 | 0.030 |
Why?
|
Interprofessional Relations | 1 | 2018 | 1011 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1257 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 578 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 3768 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2959 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2077 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 130 | 0.020 |
Why?
|
Chemoprevention | 1 | 2013 | 319 | 0.020 |
Why?
|
Dacarbazine | 1 | 2014 | 566 | 0.020 |
Why?
|
Gene Silencing | 2 | 2009 | 1538 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2017 | 1094 | 0.020 |
Why?
|
Eggs | 1 | 2011 | 184 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2014 | 598 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3586 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2013 | 1341 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15295 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2010 | 12245 | 0.020 |
Why?
|
Alopecia | 1 | 2013 | 382 | 0.020 |
Why?
|
Topotecan | 1 | 2009 | 137 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 53288 | 0.020 |
Why?
|
Immunization, Secondary | 1 | 2011 | 340 | 0.020 |
Why?
|
Aminoglycosides | 1 | 2009 | 162 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2011 | 1420 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2013 | 914 | 0.020 |
Why?
|
Constipation | 1 | 2013 | 546 | 0.020 |
Why?
|
Immunophenotyping | 2 | 2004 | 1880 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1607 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1842 | 0.020 |
Why?
|
Mice, Inbred BALB C | 2 | 2009 | 6386 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1003 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1683 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2014 | 1322 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 480 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10943 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2010 | 434 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16689 | 0.020 |
Why?
|
Registries | 2 | 2013 | 8089 | 0.020 |
Why?
|
Antigens, Viral | 1 | 2011 | 1035 | 0.020 |
Why?
|
RNA, Viral | 2 | 2007 | 2902 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2009 | 6489 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3870 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4186 | 0.020 |
Why?
|
Prevalence | 1 | 2003 | 15226 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1531 | 0.020 |
Why?
|
Autoimmunity | 1 | 2014 | 1349 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2019 | 77449 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 7913 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3507 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2886 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2017 | 3474 | 0.020 |
Why?
|
Rectum | 1 | 2010 | 904 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2014 | 19905 | 0.020 |
Why?
|
Genes, Essential | 1 | 2005 | 183 | 0.020 |
Why?
|
Sample Size | 1 | 2008 | 845 | 0.020 |
Why?
|
Genes, Viral | 1 | 2005 | 718 | 0.020 |
Why?
|
Survivors | 1 | 2014 | 2291 | 0.010 |
Why?
|
Mitoxantrone | 1 | 2004 | 152 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 2559 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2009 | 2242 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3206 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2013 | 2725 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1602 | 0.010 |
Why?
|
Etoposide | 1 | 2004 | 641 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2011 | 1477 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3508 | 0.010 |
Why?
|
Eosinophilia | 1 | 2007 | 541 | 0.010 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2002 | 130 | 0.010 |
Why?
|
Perforin | 1 | 2002 | 168 | 0.010 |
Why?
|
Interferons | 1 | 2005 | 706 | 0.010 |
Why?
|
Cervix Uteri | 1 | 2005 | 590 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 13989 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10388 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1042 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7799 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4751 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2124 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12951 | 0.010 |
Why?
|
Macrophages | 1 | 2013 | 5655 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2010 | 3036 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2008 | 18029 | 0.010 |
Why?
|
Viral Proteins | 1 | 2005 | 1900 | 0.010 |
Why?
|
Inflammation | 2 | 2010 | 10638 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15076 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2002 | 732 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 19229 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25043 | 0.010 |
Why?
|
Patient Selection | 1 | 2010 | 4215 | 0.010 |
Why?
|
Recurrence | 1 | 2009 | 8340 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2219 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2002 | 1041 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4568 | 0.010 |
Why?
|
Virus Diseases | 1 | 2002 | 711 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2004 | 1838 | 0.010 |
Why?
|
HIV | 1 | 2002 | 1604 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2004 | 5524 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9274 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 5987 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15997 | 0.010 |
Why?
|
Mice | 2 | 2009 | 81183 | 0.010 |
Why?
|
Logistic Models | 1 | 2004 | 13408 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2008 | 8863 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2002 | 21746 | 0.000 |
Why?
|